Historical Valuation
Sight Sciences Inc (SGHT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.75 is considered Undervalued compared with the five-year average of -7.38. The fair price of Sight Sciences Inc (SGHT) is between 39.35 to 53.25 according to relative valuation methord. Compared to the current price of 7.18 USD , Sight Sciences Inc is Undervalued By 81.76%.
Relative Value
Fair Zone
39.35-53.25
Current Price：7.18
81.76%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Sight Sciences Inc (SGHT) has a current Price-to-Book (P/B) ratio of 6.11. Compared to its 3-year average P/B ratio of 2.65 , the current P/B ratio is approximately 130.23% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about 149.58% higher. Sight Sciences Inc (SGHT) has a Forward Free Cash Flow (FCF) yield of approximately -8.05%. Compared to its 3-year average FCF yield of -17.68%, the current FCF yield is approximately -54.46% lower. Relative to its 5-year average FCF yield of -15.43% , the current FCF yield is about -47.83% lower.
P/B
Median3y
2.65
Median5y
2.45
FCF Yield
Median3y
-17.68
Median5y
-15.43
Competitors Valuation Multiple
AI Analysis for SGHT
The average P/S ratio for SGHT competitors is 112.70, providing a benchmark for relative valuation. Sight Sciences Inc Corp (SGHT.O) exhibits a P/S ratio of 4.75, which is -95.79% above the industry average. Given its robust revenue growth of -1.25%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for SGHT
1Y
3Y
5Y
Market capitalization of SGHT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SGHT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is SGHT currently overvalued or undervalued?
Sight Sciences Inc (SGHT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 4.75 is considered Undervalued compared with the five-year average of -7.38. The fair price of Sight Sciences Inc (SGHT) is between 39.35 to 53.25 according to relative valuation methord. Compared to the current price of 7.18 USD , Sight Sciences Inc is Undervalued By 81.76% .
What is Sight Sciences Inc (SGHT) fair value?
SGHT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Sight Sciences Inc (SGHT) is between 39.35 to 53.25 according to relative valuation methord.
How does SGHT's valuation metrics compare to the industry average?
The average P/S ratio for SGHT's competitors is 112.70, providing a benchmark for relative valuation. Sight Sciences Inc Corp (SGHT) exhibits a P/S ratio of 4.75, which is -95.79% above the industry average. Given its robust revenue growth of -1.25%, this premium appears unsustainable.
What is the current P/B ratio for Sight Sciences Inc (SGHT) as of Jan 10 2026?
As of Jan 10 2026, Sight Sciences Inc (SGHT) has a P/B ratio of 6.11. This indicates that the market values SGHT at 6.11 times its book value.
What is the current FCF Yield for Sight Sciences Inc (SGHT) as of Jan 10 2026?
As of Jan 10 2026, Sight Sciences Inc (SGHT) has a FCF Yield of -8.05%. This means that for every dollar of Sight Sciences Inc’s market capitalization, the company generates -8.05 cents in free cash flow.
What is the current Forward P/E ratio for Sight Sciences Inc (SGHT) as of Jan 10 2026?
As of Jan 10 2026, Sight Sciences Inc (SGHT) has a Forward P/E ratio of -12.15. This means the market is willing to pay $-12.15 for every dollar of Sight Sciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Sight Sciences Inc (SGHT) as of Jan 10 2026?
As of Jan 10 2026, Sight Sciences Inc (SGHT) has a Forward P/S ratio of 4.75. This means the market is valuing SGHT at $4.75 for every dollar of expected revenue over the next 12 months.